Ok et al. [38] research on the human cell lines LNCaP, DU-145, and PC-3 to carry out the anticancer outcome of emodin reveals that CXC chemokine receptor-4 (CXCR4) and HER2 expression were decreased without impacting the viability of prostate and lung cancer cells [38]. This evidence concerns the gene ERBB2 and lung cancer.